We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tobramycin Tear Concentrations

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00695435
First Posted: June 11, 2008
Last Update Posted: March 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Alcon Research
  Purpose
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.

Condition Intervention Phase
Dry Eye Drug: TOBRADEX Ophthalmic Suspension Drug: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Drug: TOBREX Ophthalmic Solution Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Tobramycin Tear Concentrations of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Versus TOBREX® Ophthalmic Solution in Normal Volunteers

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Tobramycin Tear Concentration Cmax (Maximum Concentration) [ Time Frame: 2, 4, 6, 12, and 18 minutes ]
    Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject's right eye for each treatment period.


Secondary Outcome Measures:
  • Tobramycin Tear Concentration Area Under the Curve (AUC) [ Time Frame: 2 to 18 minutes post administration ]
    Trapezoidal AUC was calculated from 2 to 18 minutes.


Enrollment: 21
Study Start Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
Drug: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
Active Comparator: TOBREX® Ophthalmic Solution
TOBREX® Ophthalmic Solution
Drug: TOBREX Ophthalmic Solution
TOBREX Ophthalmic Solution 1 drop each eye at baseline
Active Comparator: TOBRADEX® Ophthalmic Suspension
TOBRADEX® Ophthalmic Suspension
Drug: TOBRADEX Ophthalmic Suspension
TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion:

  • Visual Acuity (VA) of 0.6 logMAR or better
  • Tear meniscus height of ≥ 0.3mm at Visit 1.
  • No concomitant topical ocular medications, including artificial tears, during the study period

Exclusion

  • ocular hypertension, iritis or uveitis, glaucoma
  • ocular surgery, intraocular surgery or ocular laser procedures in either eye within the past six months
  • epithelial herpes simplex (dendritic keratitis); Vaccinia, active or recent varicella viral disease of the cornea and/or conjunctiva; ocular Rosacea; Mycobacterial infection of the eye; and / or fungal disease of the eye
  • lacrimal duct obstruction, dry eye, ocular allergies.
  • contact lens within 7 days of Visit 1.
  • ocular medications within 14 days of Visit 1.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00695435


Locations
United States, Texas
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
  More Information

Responsible Party: Michael Brubaker, Alcon
ClinicalTrials.gov Identifier: NCT00695435     History of Changes
Other Study ID Numbers: C-08-33
First Submitted: June 9, 2008
First Posted: June 11, 2008
Results First Submitted: April 27, 2009
Results First Posted: February 5, 2010
Last Update Posted: March 2, 2010
Last Verified: February 2010

Keywords provided by Alcon Research:
normal volunteers
anti-infective
tobramycin

Additional relevant MeSH terms:
Pharmaceutical Solutions
Dexamethasone acetate
Dexamethasone
BB 1101
Ophthalmic Solutions
Tobramycin
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents